有绿鞋吗？_老虎社区_美港股上老虎 - 老虎社区

1
1
收藏

改名牛牛
05-27

有绿鞋吗？

新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%

$派格生物医药-B(02565)$ 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元元。股份预期周二(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。

新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%

# 派格生物医药-B暗盘跌近4%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

1

举报

评论（1）

推荐
最新

顾坦山__Luke_
·05-27
没
回复
点赞
举报

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":439464448659512,"tweetId":"439464448659512","gmtCreate":1748309966132,"gmtModify":1748309968105,"author":{"id":3443677141101234,"idStr":"3443677141101234","authorId":3443677141101234,"authorIdStr":"3443677141101234","name":"改名牛牛","avatar":"https://static.tigerbbs.com/783ce3e2d6e257c1281d14b29514a2fb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[{"themeId":"9def1a2fcaf9e5fd93e233e38a747185","categoryId":"2929bb7468f5415f853fd96fb35d7c3b","name":"派格生物医药-B暗盘跌近4%","type":2,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":9def1a2fcaf9e5fd93e233e38a747185}&rnconfig={\"headerBarHidden\": true}","description":"5月26日，派格生物医药-B暗盘跌近4%，报15港元/股，中签一手亏300港元；公司每股定价15.6港元，每手500股，将于5月27日正式挂牌交易。PB-119主要用于T2DM及肥胖症一线治疗。全球发售总净所得款项约为2.318亿港元。杭州拱墅是一家于2018年在中国成立的有限公司，已投资超过30家公司，总投资额超过人民币25亿元。"}],"images":[],"coverImages":[],"html":"<html><head></head><body><p>有绿鞋吗？</p></body></html>","htmlText":"<html><head></head><body><p>有绿鞋吗？</p></body></html>","text":"有绿鞋吗？","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/439464448659512","repostId":1146090593,"repostType":2,"repost":{"id":"1146090593","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1748304305,"share":"https://www.laohu8.com/m/news/1146090593?lang=&edition=full","pubTime":"2025-05-27 08:05","market":"hk","language":"zh","title":"新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146090593","media":"老虎资讯综合","summary":" $派格生物医药-B(02565)$ 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元元。股份预期周二(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a> 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。</p><p>生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/14919fe317e1073f15300b43d0cb3e67\" title=\"\" tg-width=\"517\" tg-height=\"667\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/4008039a96c622d2ecb45687a7e5abce\" title=\"\" tg-width=\"514\" tg-height=\"622\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-05-27 08:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a> 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。</p><p>生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/14919fe317e1073f15300b43d0cb3e67\" title=\"\" tg-width=\"517\" tg-height=\"667\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/4008039a96c622d2ecb45687a7e5abce\" title=\"\" tg-width=\"514\" tg-height=\"622\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0","relate_stocks":{"02565":"派格生物医药-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146090593","content_text":"派格生物医药-B 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元。股份预期今日(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":255,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":439466775400904,"commentId":"439466775400904","gmtCreate":1748310119804,"gmtModify":1748314927514,"authorId":3578553421027370,"author":{"id":3578553421027370,"idStr":"3578553421027370","authorId":3578553421027370,"name":"顾坦山__Luke_","avatar":"https://static.tigerbbs.com/d1da66f052b8b61135171d9e6faffa72","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":439464448659512,"objectIdStr":"439464448659512","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"没","text":"没","html":"没","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}